Growth hormone receptor antagonist treatment reduces exercise performance in young males

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 9, 2009, Pages 3265-3272

  Goto, Kazushige ^a,b   Doessing, Simon ^a   Nielsen, Rie Harboe ^a   Flyvbjerg, Allan ^c   Kjaer, Michael ^a  

^a BISPEBJERG HOSPITAL   (Denmark)

^b WASEDA UNIVERSITY   (Japan)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE RECEPTOR; HORMONE ANTAGONIST; PEGVISOMANT; PLACEBO; SOMATOMEDIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EXERCISE; HUMAN; HUMAN EXPERIMENT; LIPID METABOLISM; LIPOLYSIS; MALE; NORMAL HUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL;

EID: 69949161266     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-0407     Document Type: Article

References (37)

1. Jenkins PJ 2001 Growth hormone and exercise: physiology, use and abuse. Growth Horm IGF Res 11(Suppl A):S71-S77 (Pubitemid 33732186)
2. Haupt HA 1993 Anabolic steroids and growth hormone. Am J Sports Med 21:468-474
3. Jenkins PJ 1999 Growth hormone and exercise. Clin Endocrinol (Oxf) 50:683-689
4. Berggren A, Ehrnborg C, Rosén T, Ellegård L, Bengtsson BA, Caidahl K 2005 Short-term administration of supraphysiological recombinant human growth hormone (GH) does not increase maximum endurance exercise capacity in healthy, active youngmenandwomenwith normal GH-insulin-like growth factor I axes. J Clin Endocrinol Metab 90:3268-3273 (Pubitemid 41014285)
5. Møller N, Jørgensen JO, Schmitz O, Møller J, Christiansen J, Alberti KG, Orskov H 1990 Effects of a growth hormone pulse on total and forearm substrate fluxes in humans. Am J Physiol 258:E86-E91 (Pubitemid 20068583)
6. Gravhølt CH, Schmitz O, Simonsen L, Bülow J, Christiansen JS, Møller N 1999 Effects of a physiological GH pulse on interstitial glycerol in abdominal and femoral adipose tissue.AmJ Physiol 277: E848-E854
7. Kanaley JA, Dall R, Møller N, Nielsen SC, Christiansen JS, Jensen MD, Jørgensen JO 2004 Acute exposure to GH during exercise stimulates the turnover of free fatty acids in GH-deficient men. J Appl Physiol 96:747-753 (Pubitemid 38140182)
8. Gibney J, Healy ML, Stolinski M, Bowes SB, Pentecost C, Breen L, McMillan C, Russell-Jones DL, Sonksen PH, Umpleby AM 2003 Effect of growth hormone (GH) on glycerol and free fatty acid metabolism during exhaustive exercise in GH-deficient adults. J Clin Endocrinol Metab 88:1792-1797 (Pubitemid 36623406)
9. HansenM,Morthorst R, Larsson B, Dall R, Flyvbjerg A, Rasmussen MH, Orskov H, Kjaer M, Lange KH 2005 No effect of growth hormone administration on substrate oxidation during exercise in young, lean men. J Physiol 567:1035-1045 (Pubitemid 41387843)
10. LangeKH,Larsson B, Flyvbjerg A, Dall R, BennekouM,Rasmussen MH, Ørskov H, KjaerM2002 Acute growth hormone administration causes exaggerated increases in plasma lactate and glycerol during moderate to high intensity bicycling in trained young men. J Clin Endocrinol Metab 87:4966-4975
11. Healy ML, Gibney J, Pentecost C, Croos P, Russell-Jones DL, Sönksen PH, Umpleby AM 2006 Effects of high-dose growth hormone on glucose and glycerol metabolism at rest and during exercise in endurance-trained athletes. J Clin Endocrinol Metab 91:320-327 (Pubitemid 43069156)
12. Cuneo RC, Salomon F, Wiles CM, Hesp R, Sönksen PH 1991 Growth hormone treatment in growth hormone-deficient adults. II. Effects on exercise performance. J Appl Physiol 70:695-700
13. Hartman ML, Weltman A, Zagar A, Qualy RL, Hoffman AR, Merriam GR 2008 Growth hormone replacement therapy in adults with growth hormone deficiency improves maximal oxygen consumption independently of dosing regimen or physical activity. J Clin Endocrinol Metab 93:125-130
14. Nass R, Huber RM, Klauss V, Müller OA, Schopohl J, Strasburger CJ 1995 Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients withhGHdeficiency acquired in adulthood. J Clin Endocrinol Metab 80:552-557
15. Whitehead HM, Boreham C, McIlrath EM, Sheridan B, Kennedy L, Atkinson AB, Hadden DR 1992 Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross-over study. Clin Endocrinol (Oxf) 36:45-52
16. Fazio S, Palmieri EA, Affuso F, Cittadini A, Castellano G, Russo T, Ruvolo A, Napoli R, Saccà L 2007 Effects of growth hormone on exercise capacity and cardiopulmonary performance in patients with chronic heart failure. J Clin Endocrinol Metab 92:4218-4223 (Pubitemid 350074734)
17. Bidlingmaier M, Wu Z, Strasburger CJ 2001 Doping with growth hormone. J Pediatr Endocrinol Metab 14:1077-1083
18. Saugy M, Robinson N, Saudan C, Baume N, Avois L, Mangin P 2006 Human growth hormone doping in sport. Br J Sports Med 40(Suppl 1):i35-i39 (Pubitemid 44032629)
19. Irving BA, Patrie JT, Anderson SM, Watson-Winfield DD, Frick KI, Evans WS, Veldhuis JD, Weltman A 2004 The effects of time following acute growth hormone administration on metabolic and power output measures during acute exercise. J Clin Endocrinol Metab 89:4298-4305 (Pubitemid 39244429)
20. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ 2002 Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 23:623-646 (Pubitemid 35191626)
21. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ 2000 Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342: 1171-1177 (Pubitemid 30211048)
22. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G 2006 Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154:467-477
23. Lindberg-Larsen R, Møller N, Schmitz O, Nielsen S, Andersen M, Orskov H, Jørgensen JO 2007 The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J Clin Endocrinol Metab 92:1724-1728 (Pubitemid 46997178)
24. Rose DR, Clemmons DR 2002 Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Horm IGF Res 12:418-424 (Pubitemid 35378831)
25. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO 2001 Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754-1759 (Pubitemid 33152999)
26. Hansen M, Morthorst R, Larsson B, Flyvbjerg A, Rasmussen MH, Orskov H, Astrup A, Kjaer M, Lange KH 2005 Effects of 2 wk of GH administration on 24-h indirect calorimetry in young, healthy, lean men. Am J Physiol Endocrinol Metab 289:E1030-E1038 (Pubitemid 43671053)
27. Lange KH, Isaksson F, Rasmussen MH, Juul A, Bulow J, Kjaer M 2001 GH administration and discontinuation in healthy elderly men: effects on body composition, GH-related serum markers, resting heart rate and resting oxygen uptake. Clin Endocrinol (Oxf) 55:77-86 (Pubitemid 34204302)
28. Moller N, Gjedsted J, Gormsen L, Fuglsang J, Djurhuus C 2003 Effects of growth hormone on lipid metabolism in humans. Growth Horm IGF Res 13(Suppl A):S18-S21 (Pubitemid 37161650)
29. Borg GA 1973 Perceived exertion: a note on "history" and methods. Med Sci Sports 5:90-93
30. Bergstrom J 1975 Percutaneous needle biopsy of skeletal muscle in physiological and clinical research. Scand J Clin Lab Invest 35:609-616
31. Juel C, Klarskov C, Nielsen JJ, Krustrup P, Mohr M, Bangsbo J 2004 Effect of high-intensity intermittent training on lactate and H+ release from human skeletal muscle. Am J Physiol Endocrinol Metab 286:E245-E251 (Pubitemid 38140316)
32. Lowry OH, Passonneau JV 1972 A flexible system of enzymatic analysis. New York: Academic
33. Jørgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LØ, Hagen C, Ørskov H 2005 Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 90:5627-5631
34. Johannsson G, Bengtsson BA, Andersson B, Isgaard J, Caidahl K 1996 Long-term cardiovascular effects of growth hormone treatment in GH-deficient adults. Preliminary data in a small group of patients. Clin Endocrinol (Oxf) 45:305-314
35. Woodhouse LJ, Asa SL, Thomas SG, Ezzat S 1999 Measures of submaximal aerobic performance evaluate and predict functional response to growth hormone (GH) treatment in GH-deficient adults. J Clin Endocrinol Metab 84:4570-4577 (Pubitemid 30677678)
36. Enevoldsen LH, Polak J, Simonsen L, Hammer T, Macdonald I, Crampes F, de Glisezinski I, Stich V, Bülow J 2007 Post-exercise abdominal, subcutaneous adipose tissue lipolysis in fasting subjects is inhibited by infusion of the somatostatin analogue octreotide. Clin Physiol Funct Imaging 27:320-326 (Pubitemid 47278528)
37. Wee J, Charlton C, Simpson H, Jackson NC, Shojaee-Moradie F, Stolinski M, Pentecost C, UmplebyAM2005GHsecretion in acute exercise may result in post-exercise lipolysis. Growth Horm IGF Res 15:397-404